Antibody-based therapeutics with enhanced adcc activity

ABSTRACT

Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.

This application claims priority to U.S. application Ser. No.60/728,947, filed on Oct. 21, 2005, which is incorporated herein byreference.

TECHNICAL FIELD

The technical field of the invention relates generally to proteinglycobiology and, more particularly, to antibody engineering andproduction as well as clinical implications of glycosylation in variousantibody-based therapeutics such as, e.g., monoclonal antibodies and Igfusion proteins.

BACKGROUND OF THE INVENTION

Antibody-based therapeutics, i.e., monoclonal antibodies (mAbs) and Fcfusion proteins, have now “come of age” as therapeutics. There are atleast eighteen mAbs and two fusion molecules on the market and more than150 are currently in clinical trials (see, e.g., Holliger et al. (2005)Nature Biotech., 23:1126-1136 and Theillaud (2005) Expert Opin. Biol.Ther., 5 (Suppl. 1):S15-S27). Indications for these therapeutics arevaried and include, e.g., organ transplantation (OKT3®, Simulect®,Zenapax®), oncology (Rituxan®, Panorex®, Herceptin®, Mylotarg®,Campath®, Zevalin®, Bexxar®, Erbitux®, Avastin®, HuMax-CD4™), infectiousdisease (Synagis®), inflammation and autoimmune disease (Humira®,Amevive®, Enbrel®), and allergic asthma (Xolair®). The therapeuticactivity of such drugs may be mediated via different mechanisms ofaction, for example, by inhibiting signaling events in target cells, bydirect induction of apoptosis, as well as by indirect immunologicmechanisms, such as antibody-dependent cell-mediated cytotoxicity (ADCC)through binding to Fc receptors and complement-dependent cytotoxicitythrough binding to C1q (both mechanisms are termed collectively as“effector functions”).

Mouse mAbs were first made by Köhler et al. in 1975 (Nature (1975)256:495-497). The first mAb that was approved for clinical use is amurine antibody (OKT3®). However, the effector functions,immunogenicity, and the pharmacokinetic properties of mouse antibodies(most of them being IgG1 or IgG2a and, in some cases, IgG2b) aregenerally not satisfactory for therapeutic uses in humans. For example,when mouse antibodies are tested with cells of human origin, the levelof ADCC is substantially lower than that with mouse cells. Furtherstudies elucidated that the antibody Fc regions are responsible foreffector functions, and that the reduced ADCC is due to a lower bindingaffinity of murine IgG Fc region to human Fcγ receptors as compared tohuman antibodies.

Much effort has been made to produce antibody-based therapeutics withdecreased immunogenicity and optimized effector functions in humans. Asa result, chimeric, humanized and fully human monoclonal antibodies andantibody-based fusion proteins have been developed. Most chimeric andhumanized antibodies, as well as antibody-based fusion molecules,contain an Fc region derived from human IgG1, because this subclassexhibits characteristics (FcγRs binding, serum half-life) and functionalproperties (ADCC, phagocytosis, endocytosis, complement activation)desirable for certain types of immune intervention.

Although some antibody-based therapeutics may function without utilizingantibody effector mechanisms, others may need to recruit the immunesystem to kill the target cells. If immune system recruitment isdesirable for a particular therapeutic, engineering the IgG Fc portionto improve effector function (e.g., improved binding to IgG receptorsand/or complement) may be a valuable enhancement.

Several strategies have been explored to enhance immune systemrecruitment, including: bispecific antibodies, in which one arm of theantibody binds to an Fcγ receptor (see, e.g., Segal et al. (1999) Curr.Opin. Immunol., 11:558-562); cytokine-IgG fusion molecules (e.g.,IL-10-Fc, IL-15-Fc); and mutation of amino acid residues responsible forbinding to FcγRs (see, e.g., Shields et al. (2001) J. Biol. Chem.,276:6591-6604).

Glycosylation of immunoglobulins can be an essential determinant ofeffector functions. Therefore, another approach to modify the effectorfunction of a particular IgG is to engineer the glycosylation pattern ofthe Fc region.

An IgG molecule contains an N-linked oligosaccharide covalently attachedat the conserved Asn297 of each of the CH2 domains in the Fc region. Theoligosaccharides found in the Fc region of serum IgGs are mostlybiantennary glycans of the complex type. Variations of IgG glycosylationpatterns include attachment of terminal sialic acid, a third GIcNAc arm(bisecting GIcNAc), a terminal galactosylation, and α-1,6-linked corefucosylation. Oligosaccharides can contain zero (G0), one (G1), or two(G2) galactoses (see FIG. 1A). The exact pattern of glycosylationdepends on the structural properties of IgG subcomponents, inparticular, CH2 and CH3 domains (Lund et al. (2000) Eur. J. Biochem.,267:7246-7257). The cell lines used to produce recombinant IgG mAbs orfusion molecules (most often derived from mouse and hamster cell lines)may also influence the synthesis of oligosaccharide chains.

The oligosaccharide moiety of glycoproteins is initially biosynthesizedfrom lipid-linked oligosaccharides to form aGIc₃Man₉GIcNAc₂-pyrophosphoryl-dolichol which is then transferred to theprotein in the endoplasmic reticulum (ER) (see FIG. 1B). Theoligosaccharide portion is then processed in the following sequence.First, all three glucose (GIc) residues are removed by glucosidases Iand II to yield Man₉GIcNAc₂-protein. The Man₉GlcNAc₂ structure may befurther processed by the removal of a number of mannose (Man) residues.Initially, four α1,2-linked mannoses are removed to give aMan₅GlcNAc₂-protein which is then lengthened by the addition of aN-acetylglucosamine (GIcNAc) residue. This new structure, theGIcNAcMan₅GIcNAc₂-protein, is the substrate for mannosidase II whichremoves the α1,3- and α1,6-linked mannoses. Thereafter, the othersugars, GIcNAc, galactose, and sialic acid, are added sequentially togive the complex types of structures often found on glycoproteins.

Several studies have investigated the relationship between IgGglycoforms and FcγRIII-dependent ADCC.

Galactose—Removal of most of the galactose residues from a humanized mAbIgG1 (Campath®) resulted in reduced complement lysis activity but had noeffect on ADCC (Boyd et al. (1995) Mol. Immunol., 32:1311-1318).However, a highly galactosylated form of a human anti-RhD monoclonal IgGis more active in ADCC assays than the agalactosyl form (Kumpel et al.(1994) Antibodies Hybridomas, 5:143-151). Thus, the impact ofgalactosylation of IgG oligosaccharide on ADCC is controversial.

Sialic Acid—The terminal sialic acid seems to have no effect on ADCC(Boyd et al. (1995) Mol. immunol., 32:1311-1318).

N-acetyl-glucosamine—Several studies have focused on the role ofbisecting GIcNAc in binding to FcγRIII and ADCC. The glycosylationpattern of a chimeric IgG1 antineuroblastoma antibody has beenengineered in CHO cells transfected withβ-1,4-N-acetylglucosaminyltransferase III (GnTIII) (Umana et al. (1999)Nature Biotech., 17:176-180; see also U.S. Pat. No. 6,602,684). Thisenzyme catalyzes the addition of bisecting GIcNAc residue to theN-linked oligosaccharide. The bisecting GIcNAc blocks the α-1,6-linkedcore fucosylation of N-glycans, since α1,6-fucosyltransferase cannotefficiently use bisecting N-glycans as substrates (Longmore et al.(1982) Carbohydrate Res., 100:365-392). IgG produced in this cell lineexhibited an increased ADCC activity. However, the contribution ofbisecting GIcNAc on effector functions as compared to core fucoseremains controversial (Shinkawa et al. (2003) J. Biol. Chem.,278:3466-3473).

Fucose—Humanized and chimeric IgG1 mAbs have been produced in a rathybridoma cell line that expresses a lower level ofα-1,6-fucosyltransferase, so that the secreted mAbs have lowerfucosylated oligosaccharide than Chinese hamster ovary (CHO)-producedIgG1 (Shinkawa et al. (2003) J. Biol. Chem., 278:3466-3473; see alsoEuropean Patent Appln. Pub. No. 1176195). These studies have shown thatnon fucosylated oligosaccharides play a more critical role in enhancingADCC than bisecting GIcNAc oligosaccharides. This report is consistentwith previous studies in which the fucose deficiency of IgG1 had noeffect on C1q binding, but provoked an increased binding to humanFcγRIIIA and allowed a higher ADCC activity (Shields et al. (2002) J.Biol. Chem., 277:26733-26740).

Attempts have been made to engineer cell lines that produce recombinantIgG with a well-defined pattern of glycosylation in the Fc region. Forexample, CHO cell lines expressing high levels of humanβ-1,4-galactosyltransferase (GT) and/or α-2,3-sialyltransferase (ST)have been made. The structure of IgG oligosaccharides produced in thesecells shows a greater homogeneity as compared with control cell lines.Overexpression of GT reduces the amount of terminal GIcNAc, whereasoverexpression of ST increases sialylation of oligosaccharides (Weikertet al. (1999) Nature Biotech., 17:116-1121).

There continues to be a need to optimize antibody-based therapeutics,and in particular, to develop methods for producing antibody-basedtherapeutics with enhanced ADCC activity.

SUMMARY OF THE INVENTION

The invention provides methods of making therapeutic antibodies and Fcfusion proteins with enhanced ADCC activity and methods of using suchtherapeutics. The invention pertains to antibody-based therapeutics thatare fully human, or otherwise contain the Fc domain of human antibodies,e.g., human, humanized or chimeric antibodies and Fc fusion moleculeswith a human Fc domain or a functional derivative thereof. In preferredembodiments, the Fc domain is from IgG, and more preferably, IgG1.

Antibodies and Fc fusion proteins made by the methods of the inventioncomprise oligomannose-type N-glycans and are further characterized byone or more of the following properties (as compared to the sameantibody or Fc fusion protein containing complex-type N-glycans):

-   -   (a) higher ADCC activity;    -   (b) higher binding affinity for FcγRIIIA (and certain other Fcγ        receptors);    -   (c) similar or higher binding specificity for the target;    -   (d) similar or higher binding affinity for the target; and    -   (e) similar or lower binding affinity for mannose receptor.

The oligomannose-type N-glycans on the antibodies and Fc fusionmolecules of the invention comprise Man₅-₉(GIcNAc)₂. Such N-glycanscontain no terminal sialic acid, galactose, or GIcNAc. In preferredembodiments, such N-glycans do not contain core fucose. In preferredembodiments, the antibody or Fc fusion protein compositions of theinvention contain predominantly Man₉(GIcNAc)₂ with diminishing amountsof the oligomannose-type oligosaccharides Man₈(GIcNAc)₂, Man₇(GIcNAc)₂,Man₆(GIcNAc)₂, and Man₅(GIcNAc)₂, while containing minor or undetectableamounts of complex-type and/or hybrid type N-glycans.

One method of making an antibody or Fc fusion protein of the inventioncomprises:

-   -   (a) providing a cell engineered to express the antibody or Fc        fusion protein;    -   (b) culturing the cell under conditions resulting in secretion        of the antibody or Fc fusion protein comprising        oligomannose-type N-glycans; and    -   (c) recovering the secreted antibody or Fc fusion protein.

Another method of making an antibody of Fc fusion protein of theinvention comprises:

-   -   (a) providing a cell engineered to express the antibody or Fc        fusion protein;    -   (b) culturing the cell under conditions resulting in expression        of the antibody or Fc fusion protein comprising        oligomannose-type N-glycans; and    -   (c) recovering the expressed antibody or Fc fusion protein.

In preferred embodiments, the engineered cell is a mammalian cell, e.g.,a CHO cell, a NSO cell, or a mouse hybridoma cell. The engineered cellmay be deficient in one or more glycosidases required for early stageprocessing of N-glycans and/or the culture conditions may be such thatthe activity of one or more of these glycosidases is inhibited. Forexample, the cell may be deficient in one or more glycosidases selectedfrom the group consisting of α-glucosidase I, α-glucosidase II, andα-mannosidase I. In addition, or alternatively, the engineered cell maybe contacted with an inhibitor of one or more glycosidases selected fromthe group consisting of α-glucosidase I, α-glucosidase II, andα-mannosidase I. In preferred embodiments, the inhibitor is an inhibitorof α-mannosidase I, e.g., the α-mannosidase I specific inhibitor,kifunensine.

The invention further provides methods of killing a target cell in amammal by administering a pharmaceutical composition comprising anantibody or Fc fusion protein of the invention to the mammal whereby theantibody mediates the killing of the target cell via ADCC. The methodsof killing a target cell include methods of treating diseases in whichantibody-directed killing of target cells is desirable, for example,various types of cancers, infectious diseases, and inflammation andautoimmune diseases.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A shows a schematic representation of various glycoforms of IgG.Sugar residues of IgG carbohydrate attached to Asn297 includeN-acetylglucosamine (GIcNAc), mannose, galactose, fucose, and sialicacid (NeuAc). The variations in IgG glycoforms depend on the attachmentof galactose, NeuAc residues and of bisecting GIcNAc to the coreGIcNAc₂Man₃GIcNAc. N-glycans may contain zero (G0), one (G1) or two (G2)galactose residues, as well as one fucose attached to the first GIcNAcon reducing end (denoted as G0F, G1F, G2F, respectively). However, themajor N-glycans found in the recombinant antibodies expressed from mostmammalian cell lines are G0F and G1F.

FIG. 1B illustrates the inhibition of the N-linked glycosylation pathwayusing various inhibitors. The processing of N-glycans on an antibody canbe inhibited by inhibitors specific for glycosidases orglycosyltransferases in the lumen of the ER or Golgi. OT denotesoligosaccharyltransferase; Glcase I & II denotes α-glucosidases I andII; Manases I & II denotes α-mannosidases I and II; GnT I & II denotesGIcNAc transferases I and II; FT denotes α-1,6 fucosyltransferase; andGT denotes β-1,4 galactosyltransferase.

FIG. 1C depicts the alignment of native sequences of human IgG Fcdomains with differences between the sequences from various IgG isotypesmarked with asterisks.

FIG. 2 shows the result of an SDS-PAGE, lectin and antibody blotting ofpurified TEM mAb A. Aliquots of 5 μg of TEM mAb A samples in reducingsample buffer were applied to each well of a 4-20% SDS-PAGE gel and thegel was stained with Coomassie Blue (FIG. 2A). Lane 1 represents IgG1from cells treated without any inhibitors; lane 2 represents IgG1 fromcells treated with mannostatin A; lane 3 represents IgG1 from cellstreated with kifunensine; lane 4 represents IgG1 from cells treated withNB-DNJ. FIG. 2B shows the results of lectin blotting of variousantibodies. The proteins (0.5 μg per sample) were separated by SDS-PAGEas described for FIG. 2A, and were transferred to a PVDF membrane. Themembrane was blotted with biotinylated lentil lectin and developed withstreptavidin-HRP. FIG. 2C shows the same membrane as in FIG. 2B thatstripped and re-blotted using anti-human Fab antibody conjugated withHRP.

FIG. 3 shows results of a MALDI-TOF mass spectrometry analysis ofcarbohydrates from TEM antibodies. Carbohydrates on TEM mAb A from cellstreated without inhibitor (A), with mannostatin A (B), kifunensine (C)and NB-DNJ (D) and carbohydrates on TEM mAb B from cells treated withoutinhibitor (E) and with kifunensine (F) were analyzed using MALDI-TOF MSanalysis.

FIG. 4 shows results of an HPLC profiling of 2-aminobenzoic acid labeledN-glycans on TEM mAb B from cells treated with kifunensine or withoutsame. HPLC profiles of 2-aminobenzoic acid labeled N-glycans on TEM mAbB from cells treated with or without kifunensine compared to variousN-glycan standards (A). HPLC profiles of 2-aminobenzoic acid labeledN-glycans on TEM mAb B from cells treated with kifunensine before andafter Endo H treatment (B).

FIG. 5 shows ADCC activity of TEM mAb from cells treated withinhibitors. (A) ADCC activity of TEM mAb A from cells treated withoutinhibitor (control) or with mannostatin A (inhibitor #1), kifunensine(inhibitor #2), NB-DNJ (inhibitor #3). (B) ADCC activity of TEM mAb Afrom cells treated without (control) or with kifunensine at variousantibody concentrations. (C) ADCC activity of TEM mAb B from cellstreated without kifunensine (control) or with kifunensine. Anti-DNP wasincluded in the assays as a negative control.

FIG. 6A shows TEM mAb A binding to target cells by flow cytometricanalysis. The antibody from cells treated without inhibitor is labeledas control, while the antibody from cells treated with mannostatin A(inhibitor #1), kifunensine (inhibitor #2), and NB-DNJ (inhibitor #3)are labeled as such. FIG. 6B shows TEM mAb B binding to target cells byflow cytometric analysis. The TEM antibodies were from cells treatedwithout (control) or with kifunensine, while anti-DNP was also includedas a negative control.

FIG. 7 shows results of a surface plasmon resonance analysis of theinteraction between soluble human FcγRIIIA (Val158) and antibodiesproduced from cells treated with kifunensine and untreated cells. Theregion of interest was expanded to show the flow of FcγRIIIA.

FIG. 8 demonstrates the interaction of the carbohydrate-binding domainof the mannose receptor with antibodies from cells treated with orwithout kifunensine. Binding of TEM mAb B from CHO cells treated with orwithout kifunensine to the carbohydrate-binding domain of the mannosereceptor was measured using BIAcore™. Mannose terminated glycoprotein(“Man3 glycoprotein”) was used as a positive control.

FIG. 9 shows results of a pharmacokinetic analysis of TEM mAb B from CHOcells treated with or without kifunensine. TEM mAb B from CHO cellstreated with or without kifunensine was injected into mice and theamount of antibodies in sera collected at various time points wasmeasured using ELISA.

FIG. 10A illustrates viability of CHO cells expressing TEM mAb B grownin shaker flasks in media with 0 to 2 μg/ml kifunensine (1 or 3treatments). FIG. 10B illustrates cell density of CHO cells expressingTEM mAb B grown in media with or without 0 to 2 μg/ml kifunensine (1 or3 treatments). The 3× treatment is indicated as “sup.” in FIGS. 10A and10B.

FIG. 11 shows results of a matrix-assisted laser desorption/ionizationtime-of-flight (MALDI-TOF) mass spectrometry analysis of carbohydratesfrom TEM antibodies from CHO cells treated with various amounts ofkifunensine for 11 days. Carbohydrates on TEM mAb B from cells treatedwithout kifunensine (FIG. 11A) or with the following additions ofkifunensine are as follows: (FIG. 11B) 0.5 μg/ml once, (FIG. 11C) 1μg/ml once, (FIG. 11D) 1.5 μg/ml once, (FIG. 11E) 2 μg/ml once, (FIG.11F) 0.5 μg/ml thrice, (FIG. 11G) 1 μg/ml thrice, (FIG. 11H) 1.5 μg/mlthrice, and (FIG. 11I) 2 μg/ml thrice (see FIG. 10). Carbohydrates onTEM mAb A from cells treated without inhibitor (FIG. 11J) or 2 μg/mlkifunensine for 11 days (FIG. 11K) (see also FIG. 12).

FIG. 12A illustrates viability of CHO cells expressing TEM mAb A grownin media with or without 2 μg/ml kifunensine for 11 days (singletreatment in 1 L spinner culture). FIG. 12B illustrates cell density ofCHO cells expressing TEM mAb A grown in media with or without 2 μg/mlkifunensine (single addition).

FIG. 13 shows ADCC activity of antibody C expressed by HEK293 cellstreated with or without kifunensine. Human PBMC were used as effectorcells, and cells which express the antigen recognized by antibody C wereused as target cells at 50:1 (FIG. 13A) and 100:1 (FIG. 13B) effectorcell to target cell ratio. IgG was used as a non-specific antibodycontrol.

FIG. 14 illustrates results of a surface plasmon resonance analysis ofthe interaction between FcγRIIIA (Val158) and antibody C from HEK293cells treated with or without kifunensine. Soluble human FcγRIIIA wascaptured on the sensor chip, and the binding of antibody C to theimmobilized FcγRIIIA was measured.

FIG. 15 shows results of a MALDI-TOF mass spectrometry analysis ofcarbohydrates of TEM mAb A from CHO cells untreated with kifunensine(FIG. 15A) or from CHO cells treated with kifunensine at 4 ng/ml (FIG.15B), 20 ng/ml (FIG. 15C), 100 ng/ml (FIG. 15D), 500 ng/ml (FIG. 15E),and 2500 ng/ml (FIG. 15F).

FIG. 16 shows results of a MALDI-TOF mass spectrometry analysis ofcarbohydrates from TEM mAb A from CHO cells treated with various amountsof kifunensine: 20 ng/ml (FIG. 16A), 40 ng/ml (FIG. 16B), 60 ng/ml (FIG.16C), 80 ng/ml (FIG. 16D), and 100 ng/ml (FIG. 16E).

FIG. 17 shows ADCC activity of TEM mAb A from CHO cells treated withvarious amount of kifunensine. FIG. 17A shows ADCC activity of theantibody expressed in the absence of kifunensisne or in the presence of2500 ng/ml kifunensine. Anti-DNP antibody was included as a negativecontrol. FIG. 17B shows ADCC activity of the same antibody from cellstreated with 20, 40, 60, 80 and 100 ng/ml kifunensine.

FIG. 18 illustrate the relationship between the percentages ofnonfucosylated glycans and specific cytotoxicity at three antibodyconcentrations (0.006, 0.06 and 0.55 μg/ml). The percentage ofnonfucosylated glycans was estimated by calculating the area of eachindividual glycan peak in MALDI-TOF MS spectra.

FIG. 19 shows results from ELISA format assays used to assess binding ofvarious FcγRs to antibody D from cells treated with kifunensine or fromuntreated cells. FIG. 19A shows binding of antibody to FcγRIA. FIG. 19Bshows binding of antibody D to FcγRIIA. FIG. 19C shows binding ofantibody D to FcγRIIB.

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID NO:1, 2, 3, and 4 are amino acid sequences of the Fc domains fromhuman IgG1, IgG2, IgG3, and IgG4, respectively.

DETAILED DESCRIPTION OF THE INVENTION

In the experiments described in the Examples, CHO and hybridoma cellsengineered to express antibodies were cultured in the presence of theα-mannosidase I inhibitor, kifunensine. The treatment of cells withkifunensine resulted in the production of antibodies carryingoligomannose-type N-glycans, while the formation of complex-typeN-glycans was blocked. The antibodies carrying oligomannose-type glycansexhibited enhanced ADCC activity as compared to the same antibodiesproduced without the kifunensine treatment. Thus, antibodies and Fcfusion proteins carrying oligomannose-type N-glycans are useful forvarious therapies in which Fc-directed killing of target cells isdesirable.

Accordingly, the invention provides methods of making therapeuticantibodies and Fc fusion proteins with enhanced ADCC activity, andmethods of using such therapeutics.

One method of making an antibody or Fc fusion protein of the inventioncomprises:

-   -   (a) providing a cell engineered to express the antibody or Fc        fusion protein;    -   (b) culturing the cell under conditions resulting in secretion        of the antibody or Fc fusion protein comprising        oligomannose-type N-glycans; and    -   (c) recovering the secreted antibody or Fc fusion protein.

Another method of making an antibody of Fc fusion protein of theinvention comprises:

-   -   (a) providing a cell engineered to express the antibody or Fc        fusion protein;    -   (b) culturing the cell under conditions resulting in expression        of the antibody or Fc fusion protein comprising        oligomannose-type N-glycans; and    -   (c) recovering the expressed antibody or Fc fusion protein.

Alternatively, antibodies comprising oligomannose-type N-glycans may beproduced by chemical linking of an unglycosylated antibody or Fc fusionprotein and a separately synthesized oligosaccharide moiety.

Antibodies and Fc Fusion Proteins

Antibodies belong to the class of proteins known as immunoglobulins.Intact antibodies are typically tetrameric glycosylated proteinscomposed of two light chains of approximately 25 kDa each and two heavychains of approximately 50 kDa each. Depending on the amino acidsequence of the constant domain of heavy chains, antibodies can beassigned to five major classes: A, D, E, G, and M, and several of thesemay be further divided into subclasses (isotypes), e.g., in human: IgG1,IgG2, IgG3, IgG4, IgA1, and IgA2, etc. Heavy and light chains eachcontain a C-terminal constant region, common to all antibodies of aparticular isotype, and an N-terminal variable region that confersbinding specificity to the antibody. The term “antibody,” as usedherein, refers to monoclonal antibodies regardless of their source ormethod of production, including, e.g., monospecific, polyspecific (e.g.,bispecific), humanized, human, chimeric, recombinant, hybrid, mutated,and CDR grafted antibodies. For example, Rituxan®, Simulect®, Remicade®,and Erbitux® are chimeric antibodies; Campath®, Zanapax®, Synagis®,Herceptin®, Mylotarg®, Xolair®, and Avastin® are humanized antibodies;and Humira® and Humax-CD4™ are fully human antibodies. It also includesportions of antibody molecules, such as scFv's, so long as suchmolecules are linked to an Fc region of an immunoglobulin. The term“polyclonal antibody,” as used herein, refers to recombinantly producedpolyclonal antibodies. Polyclonal antibodies may be used in the methodsand compositions of the invention similarly to other antibodies asdescribed herein.

Routine methods of making antibodies of these various types are wellknown and are described in, e.g., Antibody Engineering by Borrebaeck(editor), Oxford University Press, 2nd ed., 1995; Antibody Engineering:Methods and Protocols (Methods in Molecular Biology) by Lo (ed.), HumanaPress, 2003; and Antibody Engineering (Springer Lab Manuals) byKontermann et al. (eds.), Springer; 1st ed., 2001.

The terms “Fc domain,” “Fc portion,” and “Fc region” refer to aC-terminal fragment of a human antibody heavy chain, e.g., from aboutamino acid (aa) 230 to about aa 447 of γ chain or its counterpartsequence in other types of antibody heavy chains (e.g., α, δ, ε and μfor human antibodies), or a naturally occurring allotype thereof. Unlessotherwise specified, the commonly accepted Kabat amino acid numberingfor immunoglublins is used throughout this disclosure (see Kabat et al.(1991) Sequences of Protein of Immunological Interest, 5th ed., UnitedStates Public Health Service, National Institute of Health, Bethesda,Md.). The terms “non-human Fc domain,” “non-human Fc portion,” and“non-human Fc region” refer to the corresponding C-terminal fragment ofa non-human antibody heavy chain (e.g., from mouse, rat, goat, orrabbit). Non-human Fc domains can be used in the methods andcompositions of the invention similarly to human Fc domains as describedherein.

FIG. 1C illustrates an alignment of human Fc domains from IgG1 (SEQ IDNO:1), IgG2 (SEQ ID NO:2), IgG3 (SEQ ID NO:3), and IgG4 (SEQ ID NO:4).The alignment shows about 91-94% identity among these Fc domains. Acomparison of the human Fc domains to mouse Fc domains from IgG1, IgG2A,IgG2B, and IgG3 reveals identity of about 61-68%.

Immunoglobulin G (IgG) Fc receptors (FcγRs) mediate the cellulareffector function of IgG antibodies. A subset of amino acid residues inthe Fc region are involved in the binding to FcγRs. It has beendemonstrated that amino acid sequence variants that exhibit increasedbinding to FcγRIII also possess enhanced ADCC activity (Shields et al.(2001) J. Biol. Chem., 276:6591-6604). For human FcγRIIIA, this subsetincludes, for example, the following: (1) Lys274-Arg301 andTyr407-Arg416 (Sarmay et al. (1984) Mol. Immunol., 21:43-51 and Gergelyet al. (1984) Biochem. Soc. Trans.,12: 739-743); (2) Leu234-Ser239,Asp265-Glu269, Asn297-Thr299, and Ala327-Ile332 (Sondermann et al.(2000) Nature, 406:267-273, and (3) T256, K290, S298, E333, K334, A339(Shields et al. (2001) J. Biol. Chem., 276:6591-6604; see also variantsdisclosed in U.S. Patent Application No. 2004/0228856). For example, Fcvariants T256A, K290A, S298A, E333A, K334A, A339T have been described ashaving enhanced ADCC activity as compared to native sequences (see,e.g., Shields, supra). Furthermore, a number of amino acids can bemutated without any loss of ADCC function.

Accordingly, engineered Fc domains may contain only a partial or amutated amino acid sequence of the naturally occurring Fc domains, e.g.,as specified above. Therefore, for the purposes of the presentdisclosure, the terms “Fc domain” and its cognates refer not only to thenaturally occurring forms but also to engineered Fc domains. Forexample, an Fc domain may comprise a sequence, which is at least 80%,85%, 90%, 95%, or 100% identical to SEQ ID NO:n over the entire lengthof SEQ ID NO:n, wherein n=1, 2, 3, or 4.

In the methods of the invention, antibody-based therapeutics are fullyhuman, or otherwise contain the Fc domain of human antibodies, e.g.,humanized or chimeric antibodies and Fc fusion molecules with a human Fcdomain or a functional derivative thereof (e.g., a derivative that bindsto one or more Fc receptors, e.g., FcγRIIIA). The derivatives include,for example, native sequences in which conservative substitutions weremade and/or nonessential amino acids were deleted.

In preferred embodiments, the antibodies or the Fc portion is derivedfrom IgG1. However, the invention can also be practiced with otherclasses of antibodies, including IgG, IgA, IgD, IgE and IgM, andisotypes, such as, e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. Forexample, IgG4 has limited capacity to activate effector functions, whileIgAs are potent activators of ADCC. In either instance, the ADCCactivity of the antibodies or the Fc fusion molecules can be enhancedusing methods of the invention.

The specificity of the antibody toward its antigen or the specificity ofthe non-Fc portion of an Fc fusion protein for its target will varydepending on the requirements of a particular application. For example,Enbrel® contains a receptor-binding domain of a TNF receptor (p75), andAmevive® contains a CD2-binding domain of LFA-3, each fused to a humanFc domain. For example, the Fc domain may be linked to an enzyme, atoxin, a growth factor, a chemokine, or cytokine. Further, Fc fusionproteins may contain an antibody hinge region and/or a linker.

Cells and Culture Conditions

In some methods of the invention, a cell engineered to express anantibody or Fc fusion is provided. In preferred embodiments, theengineered cell is propagated in cell culture (e.g., as opposed to beinga part of a living animal (“in vivo”)). For example, the cell may be amammalian cell, e.g., a CHO cell or a human cell or a mouse hybridomacell. Examples of other types of cells that may be used for expressionof antibodies and Fc fusion proteins include mouse myeloma cells (e.g.,NS0), human embryonic kidney cells (e.g., HEK293), monkey kidney cells(e.g., COS), human epithelial carcinoma cells (e.g., HeLa), humanfibrosarcoma cells (e.g., HT-1080), baby hamster kidney cells, yeastcells, insect cells, and others (see, e.g., Fernandez et al. (eds.) GeneExpression Systems, Academic Press, 1999). Any cell compatible with thepresent invention and appropriate culture conditions may be used.

The engineered cell may be deficient in one or more glycosidasesrequired for early stage processing of N-glycans and/or the cultureconditions may be such that the activity of one or more of theseglycosidases is inhibited. As a result of one or both of theseconditions, oligosaccharide synthesis is shifted towardoligomannose-type species.

For example, the cell may be deficient in one or more glycosidasesselected from the group consisting of α-glucosidase I, α-glucosidase II,and α-mannosidase I. Cells deficient in a glycosidase of interest can beengineered using methods as described, e.g., in Tymms et al. (eds.) GeneKnockout Protocols (Methods in Molecular Biology), Humana Press, 1sted., 2001; and in Joyner (ed.) Gene Targeting: A Practical Approach,Oxford University Press, 2nd ed., 2000. For instance,glycosidase-deficient cells can be engineered using lectin selection asdescribed in Stanley et al. (1975) Biochemistry, 72 (9):3323-3327.

In addition, or alternatively, the engineered cell may be contacted withan inhibitor of one or more glycosidases selected from the groupconsisting of α-glucosidase I, α-glucosidase II, and α-mannosidase I.Inhibitors of these enzymes may be, for example, small molecules orsmall interfering RNAs (siRNAs).

siRNAs are short (20-25 nt) double stranded RNAs that inhibit aglycosidase of interest via post-transcriptional gene silencing. Aglycosidase-specific siRNA may be prepared and used as described in U.S.Pat. No. 6,506,559 and/or using other suitable methods (see, e.g.,Appasani (ed.) RNA Interference Technology: From Basic Science to DrugDevelopment, Cambridge University Press, 1st ed., 2005; and Uei-Ti etal. (2004) Nucleic Acids Res., 32 (3):936-948).

Examples of small molecule α-glucosidase I inhibitors includecastanospermine (Pan et al. (1983) Biochemistry, 22:3975-3984,deoxynojirimycin (DNJ; Hettkamp et al. (1984) Eur. J. Biochem.,142:85-90) and N-alkyl and N-alkenyl derivatives thereof (e.g.,N-butyl-DNJ); 2,5-dihydromethil-3,4-dihydroxypyrrolidine (DMDP; Elbeinet al. (1984) J. Biol. Chem., 259:12409-12413); and australine (Molyneuxet al. (1988) J. Nat. Prod., 51:1198-1206).

Examples of small molecule α-glucosidase II inhibitors include DNJ andN-alkyl and N-alkenyl derivatives thereof; and MDL 25637 (Hettkamp etal. (1984) Eur. J. Biochem., 142: 85-90; Kaushal et al. (1988) J. Biol.Chem., 263: 17278-17283).

Examples of small molecule a-mannosidase I inhibitors includedeoxymannojirimycin (DMJ; Legler et al. (1984) Carbohydr. Res.,128:61-72) and derivatives thereof (e.g., N-methyl derivative asdescribed in Bosch et al. (1985) Virology, 143:342-346),1,4-dideoxy-1,4-imino-D-mannitol (DIM; Fleet et al. (1984) J. Chem. Soc.Chem. Commun., 1240-1241 and Palmarzyk et al. (1985) Arch. Biochem.Biophys., 243:35-45), and kifunensine (Elbein (1990) J. Biol. Chem.,265:15599-15605).

In preferred embodiments, the engineered cells are cultured in thepresence of the a-mannosidase I inhibitor, kifunensine. In certainembodiments, kifunensine may be used at a concentration of 0.01 to 100μg/ml, 0.01 to 75 μg/ml, 0.01 to 50 μg/ml 0.01 to 40 μg/ml, 0.01 to 30μg/ml, 0.01 to 20 μg/ml, 0.1 to 10 μg/ml, 0.1 to 2.0 μg/ml, or 1 to 0.5μg/ml for a period of at least 12, 24, 48, 72 hours or 4, 7, 10, 20 daysor longer, or continuously. In nonlimiting illustrative embodiments, CHOor hybridoma cells are incubated with about 0.5-10 μg/ml kifunensine forover 10 days.

Characteristics of Antibodies Produced

Antibodies and Fc fusion proteins made by the methods of the inventioncomprise oligomannose-type N-glycans and are further characterized byone or more of the following properties (vis-à-vis the same antibody orFc fusion protein with complex-type N-glycans (“wild-type”)):

-   -   (a) higher ADCC activity;    -   (b) higher binding affinity for FcγRIIIA (and certain other Fcγ        receptors);    -   (c) substantially same or better binding specificity for the        target;    -   (d) substantially same or higher binding affinity for the        target; and    -   (e) substantially same or lower binding affinity for mannose        receptor.

“ADCC activity” refers to the ability of an antibody or Fc fusionprotein to elicit an ADCC reaction. ADCC is a cell-mediated reaction inwhich antigen-nonspecific cytotoxic cells that express FcRs (e.g.,natural killer (NK) cells, neutrophils, and macrophages) recognizeantibody bound to the surface of a target cell and subsequently causelysis of (i.e., “kill”) the target cell. The primary mediator cells arenatural killer (NK) cells. NK cells express FcγRIII only, with FcγRIIIAbeing an activating receptor and FcγRIIIB an inhibiting one; monocytesexpress FcγRI, FcγRII and FcγRIII (Ravetch et al. (1991) Annu. Rev.Immunol., 9:457-92). ADCC activity can be assessed directly using an invitro assay, e.g., a ⁵¹Cr release assay using peripheral bloodmononuclear cells (PBMC) and/or NK effector cells as described in theExamples and Shields et al. (2001) J. Biol. Chem., 276:6591-6604, oranother suitable method. ADCC activity may be expressed as aconcentration of antibody or Fc fusion protein at which the lysis oftarget cells is half-maximal. Accordingly, in some embodiments, theconcentration of an antibody or Fc fusion protein of the invention, atwhich the lysis level is the same as the half-maximal lysis level by thewild-type control, is at least 2-, 3-, 5-, 10-, 20-, 50-, 100-fold lowerthan the concentration of the wild-type control itself. Additionally, insome embodiments, such as, e.g., TEM mAb A, the antibody or Fc fusionprotein of the invention may exhibit a higher maximal target cell lysisas compared to the wild-type control. For example, the maximal targetcell lysis of an antibody or Fc fusion protein of the invention may be10%, 15%, 20%, 25% or more higher than that of the wild-type control.

The binding affinity of an antibody or Fc fusion protein to its targetas well as to Fc receptors and mannose receptors may be assessed usingsurface plasmon resonance as described in the Examples and/or ELISA asdescribed in Shields et al. (2001) J. Biol. Chem., 276:6591-6604 orother suitable method. In some embodiments, the binding constant K_(d)of an antibody or Fc fusion protein for FcγRIIIA may be above that ofthe wild-type control by at least 2-, 5-, 10-, 50-fold, or higher. Thebinding constant K_(d) of an antibody or Fc fusion protein of theinvention for its target (e.g., antigen) may be substantially the same(i.e., ±50%) as the wild-type control or above it. In some embodiments,the binding constant K_(d) of an antibody or Fc fusion protein of theinvention for mannose receptors may be substantially the same (i.e.,±50%) as the wild-type control or below it.

In some embodiments, certain pharmacokinetic parameters of an antibodyor Fc fusion protein of the invention are same or better that those ofwild-type control. For example, in some embodiments, eliminationhalf-life (t_(1/2)) and/or the area under the concentration curve (AUC)may be substantially the same (i.e., ±50%) as the wild-type control orabove it. Pharmacokinetic parameters can be measured in humans or usingan appropriate animal model (e.g., as described the Examples) or othermethods (see, e.g., Shargel et al. (1995) Applied Biopharmaceutics andPharmacokinetics, 4th ed., McGraw-Hill/Appleton).

The binding specificity of an antibody or Fc fusion protein can bedetermined by, e.g., flow cytometry as described in the Examples,Western blotting, or another suitable method. In some embodiments, anantibody or Fc fusion protein of the invention is directed against ahuman target protein (a human antigen in case of an antibody) expressedon the surface of a target cell. In some embodiments, it may be directedagainst a soluble antigen. In some other embodiments, an antibody or Fcfusion protein of the invention is directed against a pathogenic target(e.g., viral or bacterial protein). The antibody or Fc fusion proteinmay be either specific to a human target or may cross-react withcorresponding targets from other species.

The oligomannose-type N-glycans on the antibodies and Fc fusionmolecules of the invention comprise one or more oligomannose-typeoligosaccharides selected from the group consisting of Man₉(GIcNAc)₂,Man₈(GIcNAc)₂, Man₇(GIcNAc)₂, Man₆(GIcNAc)₂, and Man₅(GIcNAc)₂.

Accordingly, in preferred embodiments, the antibody and Fc fusionprotein compositions of the invention contain predominantlyMan₉(GIcNAc)₂ with diminishing or undetectable amounts of theoligomannose-type N-glycans Man₈(GIcNAc)₂, Man₇(GIcNAc)₂, Man₆(GIcNAc)₂,and Man₅(GIcNAc)₂, while containing minor (e.g., less than 10% relativeto all N-glycans) or undetectable amounts of complex type N-glycans(such as, e.g., G0, G1, G2, G0F, G1F, G2F, and G0F-Gn).

In some embodiments, compositions produced by the methods of theinvention contain at least 20%, 30%, 40%, 50%, 60%, 70%, 90% or more (bymolar ratio relative to all N-glycans) oligomannose-type glycansMan₅-₉(GIcNAc)₂. In some embodiments, the Man₅-₉(GIcNAc)₂ in thecompositions of the invention are substantially unfucosylated, i.e.,they contain less than 30%, 25%, 20%, 15%, 10%, 5%, 1% (by molar ratio,relative to all N-glycans) or less fucose. In some embodiments, thecompositions contain less than 30%, 20%, 10%, 5%, 1% (by molar ratio,relative to all N-glycans) or less Man₅(GIcNAc)₂ and/or Man₆(GIcNAc)₂glycans. In some embodiments, the compositions contain minor (i.e., lessthan 10% by molar ratio relative to all N-glycans) or undetectableamounts of Man₄(GIcNAc)₂. In some embodiments, the compositions containless than 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1% (by molarratio, relative to all N-glycans) or less complex-type glycans.

Glycan composition can be assessed using, e.g., lectin blotting, HPLCand/or mass spectrometry analysis as described in the Examples and/orother methods as described in, e.g., Townsend et al. (1997) Techniquesin Glybiology, CRC Press.

Uses

The invention further provides methods of killing a target cell in amammal, comprising administering an antibody or Fc fusion protein of theinvention to the mammal whereby the antibody mediates the killing of thetarget cell via ADCC. The target cell in the methods of the inventionmay be a cancerous cell, an infected cell, a cell of the immune system(e.g., a B cell or a T cell), or any other cell for which cell killingis desired. The mammal to whom the antibody or Fc fusion protein isadministered may be a human, or of another species, e.g., a rodent.

The methods of killing a target cell include methods of treatingdiseases in which antibody-directed killing of target cells isdesirable, by administering a pharmaceutical composition comprising anantibody or Fc fusion protein of the invention to a mammal. In additionto the antibody or Fc fusion protein, the pharmaceutical compositionscomprise a pharmaceutically acceptable excipient. The formulation ofpharmaceutical compositions varies depending on the intended route ofadministration, the biological activity of the active ingredient andother parameters (see, e.g., by Rowe et al. (2003) Handbook ofPharmaceutical Excipients, 4th ed., APhA Publications.)

Antibody-based therapeutics of the invention are broadly applicable toany disease or condition in which antibody-directed killing of targetcells is desirable. Diseases and conditions to be treated withcompositions of the invention include various types of cancers,infectious diseases, inflammatory and immune-mediated diseases(including autoimmune diseases), renal diseases, transplantation (e.g.,stem cell or organ transplantation), etc.

Examples of cancers that may be amenable to treatment with compositionsof the invention include, without limitation, leukemias, lymphomas,myelomas and other cancers of hematopoietic origin, melanomas and othercancers of the skin, and cancers of the kidney, breast, lung, bone,colon, rectum, uterus, cervix, ovaries, pancreas, prostate, testes,bladder, stomach, brain, and thyroid. Additional cancers include thoselisted in Table 1 of U.S. Pat. No. 6,359,193.

Examples of infectious diseases that may be amenable to treatment withcompositions of the invention include viral infections (e.g., RSV, HCV,and West Nile virus).

Examples of inflammatory and immune-mediated diseases that may beamenable to treatment with compositions of the invention includerheumatoid arthritis (RA), psoriasis, systemic lupus erythematosus (SLE)and lupus nephritis, insulin-dependent diabetes mellitus (IDDM; type Idiabetes), inflammatory bowel disease (IBD), graft-versus-host disease(GVHD), celiac disease, autoimmune thyroid disease, Sjögren's syndrome,autoimmune gastritis, autoimmune hepatitis, cutaneous autoimmunediseases, autoimmune dilated cardiomyopathy, myocarditis, multiplesclerosis (MS), myasthenia gravis (MG), vasculitis (e.g., Takayasu'sarteritis and Wegener's granulomatosis), autoimmune diseases of themuscle, autoimmune diseases of the testis, autoimmune ovarian disease,and autoimmune uveitis.

Additional disorders that may be amenable to treatment with compositionsof the invention include fibrosis (e.g., kidney fibrosis), Addison'sdisease, Syndenham's chorea, ulcerative colitis, polymyalgia, perniciousanemia, and pernicious anemia.

“Administration” is not limited to any particular delivery system andmay include parenteral (including subcutaneous, intravenous,intramedullary, intraarticular, intramuscular, or intraperitonealinjection), topical, transdermal, and oral. Administration may occur ina single dose or in repeat administrations. The antibodies and Fc fusionproteins may be administered in combination with other therapeuticagents. For example, in treating cancers, antibodies and Fc fusionproteins may be combined with chemotherapeutic agents (see, e.g., PCTApplication Pub. No. WO 2005/050200), radiation and other treatments(see, e.g., Schwartz et al. (ed.) Combination Cancer Therapy: Modulatorsand Potentiators, Humana Press, 2005).

Most commonly, antibodies and Fc fusion proteins are administered in anoutpatient setting by weekly administration at 0.1-50 mg/kg, e.g., 1-10μg/kg, doses by slow intravenous (IV) infusion. The appropriatetherapeutically effective dose, routes of administration and regimenswill be determined by a physician based on the biological activity ofthe particular antibody in question; exemplary doses for marketedantibodies can be found in 2005 Physicians' Desk Reference (PDR) ThomsonHealthcare, 59th ed., 2004; and Remington: The Science and Practice ofPharmacy, eds. Gennado et al., 20th ed, Lippincott, Williams & Wilkins,2000.

The following Examples provide illustrative embodiments of theinvention. The Examples do not in any way limit the invention.

EXAMPLES Example 1

Treatment of Cells and Purification of Antibodies

Hybridoma cells expressing TEM mAb A, an antibody against a tumorvascular associated antigen, were grown in medium containing 1% fetalbovine serum with low IgG (Invitrogen Corp.), 5 μg/ml bovine insulin, 5μg/ml human transferrin, 0.01 mM ethanolamine and 25 nM sodium selenite.Cells were treated once with the following inhibitors: 20 μg/mlmannostatin A, and 0.5 mM NB-DNJ for 4 days; and twice with 2 μg/mlkifunensine at days 0 and 2; or cultured without inhibitors (“control”).

CHO cells expressing TEM mAb B, a different antibody against a tumorvascular associated antigen, were grown in CD-CHO media with 4 mMglutamine. Cells were cultured for three days, while being treated with2 μg/ml kifunensine at days 0 and 2 or cultured without kifunensine(“control”). Antibodies in the media were purified using a Protein ASepharose™ column. After loading the column, the column was washedextensively with 15 column volumes of PBS buffer, pH 7.1, or HEPESbuffer, pH 8.0, and the antibodies were eluted with 50 mM sodiumsuccinate buffer, pH 3.0 or pH 3.75. The eluates were collected in tubesat 1 ml per fraction with 1 M Tris buffer, pH 8.0. The purifiedantibodies were buffer-exchanged into PBS buffer, pH 7.2, and theprotein concentration was determined using A280. The purity ofantibodies was evaluated on a 4-20% SDS-PAGE and stained with Coomassieblue. More than 90% purity was observed for TEM mAb A (FIG. 2A). Similarresults were obtained for TEM mAb B.

Example 2

Lectin Blotting

Antibody samples purified as described in Example 1 were resolved on a4-20% SDS-PAGE and transferred to a PVDF membrane. The membrane wasincubated one hour with biotinylated lentil lectin (a lectin specificfor α-1,6 linked fucose) in 50 mM Tris buffer, pH 7.4, containing 0.5 MNaCl, 1 mM CaCl₂, 1 mM MgCl₂, 1% BSA and 0.5% Tween 20. Thereafter, themembrane was washed and incubated with streptavidin-HRP in the samebuffer and then developed using a chemoluminescent reagent.

The results for TEM mAb A are shown in FIG. 2B. The results indicatethat the antibody from cells treated with kifunensine containedsignificantly less N-glycans with α-1,6-linked fucosylated structures.(Similar results were observed for TEM mAb B samples.)

The same membrane was stripped using stripping buffer (Pierce),incubated with an anti-human Fab-HRP antibody and developed using achemoluminescent reagent. The results (FIG. 2C) confirmed equal loadingof the antibody samples.

Example 3

MALDI-TOF Mass Spectrum Analysis of Oligosaccharides

N-linked glycans from antibodies purified as described in Example 1 werereleased with PNGase F. After filtration through 10 kDa filters, thefiltrates were treated with Dowex AG-50 (H⁺), AG501, and C18 ziptipsequentially. Aliquots of samples were applied to a target, followed bysDHB matrix. The MALDI-TOF mass spectra were acquired using a Voyager-DEPRO Biospectrometry Workstation (Applied Biosystems, Foster City,Calif., USA) in the positive-ion and reflective mode.

The results from the analysis of TEM mAb A, as described in Example 1,are shown in FIG. 3 and Table 1. TABLE 1 Theo- Observed^(a) retical^(a)Groups m/z m/z Structures Control 1485.9867 1485.5344(HexNAc)₂(Deoxyhexose)₁ + (peak 1) (Man)₃(GlcNAc)₂ G0F 1648.10701647.5874 (Hex)₁(HexNAc)₂(Deoxyhexose)₁ + (peak 2) (Man)₃(GlcNAc)₂ G1FManno- 1486.0117 1485.5344 (HexNAc)₂(Deoxyhexose)₁ + statin (peak 1)(Man)₃(GlcNAc)₂ G0F treatment 1648.1381 1647.5874(Hex)₁(HexNAc)₂(Deoxyhexose)₁ + (peak 2) (Man)₃(GlcNAc)₂ G1F Kifunen-1743.9953 1743.5814 (Hex)₅ + (Man)₃(GlcNAc)₂ sine (peak 1) Man8 withoutfucose treatment 1906.1454 1905.6344 (Hex)₆ + (Man)₃(GlcNAc)₂ (peak 2)Man9 without fucose NB-DNJ 1485.9195 1485.5344 (HexNAc)₂(Deoxyhexose)₁ +treatment (peak 1) (Man)₃(GlcNAc)₂ G0F 1648.0156 1647.5874(Hex)₁(HexNAc)₂(Deoxyhexose)₁ + (peak 2) (Man)₃(GlcNAc)₂ G1F 2068.26412067.6874 (Hex)₇ + (Man)₃(GlcNAc)₂ (peak 3) Man9 containing one glucosewithout fucose^(a)m/z values are for the [M + Na]⁺ ions.

The data indicate that TEM antibodies from cells treated withkifunensine contained mainly Man₉GIcNAc₂ (Man9), Man₈GIcNAc₂ (Man8) andMan₇GIcNAc₂ (Man7) without fucose as major N-glycans (FIGS. 3C and 3F)while the major N-glycans in the same antibodies from control cells werefucosylated biantennary species with 0 or 1 galactose, includingGIcNAc₂Man₃GIcNAc₂Fuc₁ (GOF) and GaI₁GIcNAc₂Man₃GIcNAc₂Fuc₁ (G1F) (FIGS.3A and 3E). The carbohydrates in TEM mAb A from cells treated withmannostatin A were similar to those found in control antibody (FIG. 3B).However, there were significant amounts of GIc₁Man₉GIcNAc₂ (Man9GIc) inTEM mAb A from cells treated with NB-DNJ (FIG. 3D). The data indicatethat kifunensine is more effective in blocking the glycosylation tocomplex-type structures than NB-DNJ. No alteration in glycosylationoccurred in the antibody expressed in cells treated with mannostatin A.

Example 4

HPLC Analysis of 2-aminobenzoic Acid Labeled N-Glycans

The analysis was performed as described in Anumula et al. (1998)Glycobiology, 8:685-694, with minor modifications. N-glycans releasedfrom 200 μg of antibody were purified by Biodialyzer overnight. Half ofthe material was labeled with 2-aminobenzoic acid and cleaned withGlycoClean S cartridge (Prozyme). Several N-glycan standards were alsolabeled with 2-aminobenzoic acid. 2-aminobenzoic acid labeled glycanswere separated on an Asahipak NH2P-50 4D column (4.6×250 mm, Phenomenex)using an HP1100 system equipped with a fluorescence detector (ex. at 230nm and em. at 425 nm). The column was equilibrated in 70% solvent A (2%acetic acid and 1% inhibited tetrahydrofuran in acetonitrile).2-aminobenzoic acid labeled glycans were eluted at 50° C. using a lineargradient of 30-50% solvent B (5% acetic acid, 3% triethylamine, and 1%inhibited tetrahydrofuran in water) over 60 minutes at a flow rate of 1ml/min. Subsequent washes with 95% solvent B and 30% solvent B were usedto clean and re-equilibrate the column. Final injection amount equaledto a pool of glycans released from 20 μg of antibody.

The results of the HPLC analysis of fluorescence labeled N-glycansconfirmed the results from MALDI-TOF mass spectrometry analysis (Example3). For control TEM mAb B, the first peak in HPLC aligned with the G0Fstandard (FIG. 4A). The other two remaining peaks are presumed to be G1Fand G2F. In the spectra of TEM mAb B from cells treated withkifunensine, the last and major MALDI peak aligned with the Man9standard. However, the presumed Man7 and Man8 peaks from the antibodydid not align with the Man7 and Man8 standards. The difference inelution time between the Man7 and Man8 standards and the sample peakscould be attributed to different isomer compositions of thosestructures. Endo H digestion of fluorescently labeled N-glycans from TEMmAb B from cells treated with kifunensine resulted in the disappearanceof the Man9, Man8 and Man7 peaks, confirming their oligomannosestructural identity (FIG. 4B).

Example 5

ADCC Assays

The antibody samples from cells treated with different inhibitors wereanalyzed for ADCC as follows. Target cells, breast cancer cell linesincluding SKOV3 or MDA231 with TEM antigens, were resuspended in growthmedia and labeled with Na₂ ⁵¹CrO₄ in a 37° C. incubator with 5% CO₂ for1-2 hrs. The cells were then washed, resuspended in the RPMI medium andmixed with various concentrations of antibodies and effector cells at aneffector:target ratio of 100:1 or 200:1. The effector cells wereperipheral blood mononuclear cells (PBMC) prepared usingFicoll-Hypaque-gradient centrifugation. The cells and antibodies wereincubated for 4-18 hrs at 37° C. in a humidified incubator with 5% CO₂.After the incubation, the intact cells were removed by centrifugation orlyzed using detergent. The radioactivity in the supernatants fromexperimental release (E), spontaneous release (S, release from targetwithout effector cells and antibody), and total lysate (T, release fromtarget cells treated with detergent) was determined using an irradiationcounter. The percent specific lysis was calculated as follows:[(E-S)/(T-S)]*100.

The results from ADCC assays of TEM mAb A antibodies from hybridomacells expressed in the presence of various inhibitors are shown in FIG.5A. The data show that TEM mAb A from hybridoma cells treated withkifunensine (inhibitor #2) had the highest ADCC activity among theantibody samples. The antibody from cells treated with NB-DNJ (inhibitor#3) showed a lower ADCC activity than the same antibody from thekifunensine-treated cells, but a higher activity as compared to all therest of the samples. The ADCC activity of TEM mAb A from cells treatedwith mannostatin A (inhibitor #1), was comparable to the controlsamples. The results indicated that the ADCC activity correlated withthe glycosylation patterns of the antibodies.

A similar ADCC assay was performed with TEM mAb A produced bykifunensine (inhibitor #2)-treated cell as well as untreated controlcells. The results (FIG. 5B) showed a 10-100-fold increase in ADCCactivity for the antibody from cells treated with kifunensine ascompared to that from hybridoma cells treated without inhibitor(control). Another similar ADCC assay was also performed on TEM mAb Bfrom CHO cells treated with kifunensine and untreated controls. Theresults (FIG. 5C) showed that TEM mAb B from kifunensine-treated cellsproduced antibody with a higher ADCC activity than the controls.

Example 6

Flow Cytometry Analysis

A FACS® assay was performed to determine the binding of TEM mAb A andTEM mAb B to antigens on target cells. 2×105 target cells were incubatedwith antibody from cells treated with various inhibitors as described inExample 5. The incubating solution contained 1 to 10 μg/ml antibody inPBS with 5% fetal bovine serum and 5% goat serum. The bound antibody wasdetected with FITC-labeled goat anti-human Fc and analyzed using a FACSCalibur (Becton Dickinson).

The results of the FACS® analysis indicate that despite the differencein the ADCC activities (see Example 5), TEM mAb A (FIG. 6A) and TEM mAbB (FIG. 6B) bound equally well to the cell surface antigens regardlessof whether they were produced with or without kifunensine.

Example 7

Fc Receptor and Mannose Receptor Binding

Since ADCC activity is correlated with the binding of the antibody orantibody-antigen complex to Fc receptors, especially FcγRIIIA, theinteraction of antibodies with FcγRIIIA was investigated using surfaceplasmon resonance. TEM mAb B was immobilized on CM5 chip with a TEMantigen. Soluble recombinant human FcγRIIIA (Val158) was then injectedinto BlAcore™ 3000 biosensor unit to monitor the binding.

The results (FIG. 7) indicated a higher FcγRIIIA binding to TEM mAb Bexpressed in the presence of kifunensine as compared to the sameantibody expressed in the absence of the inhibitor. The increasedbinding of antibody from kifunensine-treated cells to the Fc receptorcorrelated with the enhancement of ADCC activity of these antibodies.

The in vivo clearance through the mannose receptor is known to be quiterapid. Accordingly, the binding of the TEM mAb B to the mannose receptorwas investigated using surface plasmon resonance (BIAcore™). A solublemannose receptor containing carbohydrate recognition domain (CRD) 4-7and a HPC tag was immobilized to a CM5 BIAcore surface (200 RU). Theantibodies were diluted to 100 nM in HBS binding buffer (10 mM HEPES, pH7.0, 150 mM NaCl) containing 10 mM CaCl₂ and 0.005% surfactant P20 andinjected into a BIAcore™ 3000 biosensor unit to monitor the binding.Mannose terminated glucocerebrosidase (100 nM) was included as apositive control.

The results of the mannose receptor binding experiments (FIG. 8) showedthat the binding of the antibody from either kufinensine-treated orkifunensine untreated cells was much lower than the control (proteinwith oligomannose type N-glycans such as Man₃(GIcNAc)₂ (“Man3glycoprotein”). These results suggest that, when administered in vivo,the antibodies carrying oligomannose type glycans are not likely to berapidly cleared by the mannose receptor.

Example 8

Antibody Affinity Analysis

The binding affinity of TEM mAb B expressed in the presence ofkifunensine was compared to the antibody expressed in the absence of theinhibitor using surface plasmon resonance (BIAcore™) as follows. Theaffinity of antibody was measured using CM5 chips carrying immobilizedantigen. Antibodies diluted in different concentrations using HBS-EP orPBS containing 0.005% surfactant P20 running buffer were injected induplicate or triplicate for 5 min, followed by 5 min dissociation. 40 mMHCl was used to regenerate the surface. A 1:1 binding model was thenused to fit the data.

The results (Table 2) showed comparable affinities of TEM mAb Bexpressed in the presence or in the absence of kifunensine, when a 1:1binding model was used to fit the data. The sensorgrams showed nearlyidentical binding curves for both of the samples at each concentrationtested. These results were consistent with the data on the antibodybinding to the antigen on target cells using FACS (Example 6). TABLE 2TEM-1 mAb B k_(a) ^(a) k_(d) ^(b) K_(A) ^(c) K_(D) ^(d) (CHO) (1/Ms ×10⁶) (1/s × 10⁻³) (1/M × 10⁹) (M × 10⁻⁹) untreated 1.16 1.14 1.01 0.99kifunensine 1.44 1.18 1.22 0.82 treated^(a)on rate;^(b)off rate;^(c)association rate;^(d)dissociation rate.

Example 9

Pharmacokinetic Analysis

A pharmacokinetic analysis was performed using mice injected with TEMmAb B expressed in the presence or absence of kifunensine. TEM mAb Binjected into BALB/c mice via tail vein at 5 mg/kg. There were ten miceper group. The blood was collected at 1, 6 hours and 1, 2, and 7 daysafter injection and kept frozen. The amount of TEM mAb B in the serumwas measured using ELISA with anti-human antibodies.

The results are presented in FIG. 9. There was no significant differencein the apparent elimination half-life of TEM mAb B samples from cellstreated with or without kifunensine. Little difference in the amount ofboth antibodies was observed in the sera of mice on day 7post-injection. The results suggest that oligomannose-type glycans onTEM mAb did not contribute to significant clearance via the mannosereceptor based on the in vitro mannose receptor binding data (Example 7)and the pharmacokinetics.

Example 10

Production of Antibody in Batch Cultures

The production of TEM mAb B from batch cultures treated with variousamounts of kifunensine or untreated was evaluated. CHO celis in shakerflasks were treated with 0, 0.5, 1, 1.5, or 2 μg/mi in a single or threeadditions (4 days apart) and cultured for 11 days. Cell viability (usingtrypan blue) and cell counts were assessed at least every other day.

The antibody VPR (volume production rate) during the 11 days in culturewith a single kifunensine treatment at concentrations from 0.5 to 2μg/ml was comparable to that in the triple treatments at the sameamounts of the inhibitor. The results showed similar amount of antibodyproduced under different conditions (Table 3). The cell viability wascomparable for different conditions (FIG. 10A), while the cell densitywas lower in kifunensine-treated cells. The treatment of cells withthree additions of kifunensine resulted in a much lower cell densitythan that in the untreated control or the single kifunensine treatment(FIG. 10B and Table 3).

The effect of kifunensine on the production of TEM mAb A in batchcultures was likewise tested. Cells were cultured in 1 L spinners for 11days in the media with 2 μg/ml kifunensine (single addition) or without.Cell viability (using trypan blue) and cell counts were assessed atleast every other day. TABLE 3 Xvmax^(b) SPR (average)^(c) Sample VPR(mg/l)^(a) (×10⁶ cells) Pg/cell/day #1, untreated 350.6 4.3 14.9 #2, 0.5μg/ml kif 390.1 3.5 20.0 #3, 1 μg/ml kif 386.9 2.7 26.0 #4, 1.5 μg/mlkif 387.6 3.8 18.6 #5, 2 μg/ml kif 371.8 2.1 31.7 #6, 0.5 μg/ml kif sup.3× 397.7 3.5 21.0 #7, 1 μg/ml kif sup. 3× 376.1 1.6 43.6 #8, 1.5 μg/mlkif sup. 3× 377.7 1.6 41.9 #9, 2 μg/ml kif sup. 3× 341.0 1.7 36.5^(a)volume production rate;^(b)viable cells at day of peak cell density;^(c)specific production rate.

The results showed similar cell viability and cell counts (FIG. 12).About 60% increase in the antibody titer was observed with kifunensineas compared to controls. The results from MALDI-TOF mass spectrumanalysis also indicated the presence of Man8- and Man9 ontainingN-glycans as major species in TEM mAb A from cells treated withkifunensine (FIG. 11K). The carbohydrates in TEM mAb B purified fromthese cultures contained similar Man9- and Man8-containing N-glycansregardless of the amount of kifunensine used (FIG. 11 and Table 4). Asingle kifunensine treatment at a concentration of 0.5 μg/ml was enoughto result in the production of oligomannose-type structures.

Kifunensine treatment did not affect the cell viability or antibodyproduction. Cell growth was retarded, especially in the high dose andmultiple kifunensine treatments, in CHO cells in shaker flask but not soin the spinner cultures, suggesting that the kifunensine treatment mayhave resulted in an increased antibody expression and/or secretionefficiency. TABLE 4 Observed^(a) Theoretical^(a) Groups m/z m/zStructures #1, 1486.1199 1485.5344 (HexNAc)₂(Deoxyhexose)₁ + untreated(peak 1) (Man)₃(GlcNAc)₂ G0F 1648.2581 1647.5874(Hex)₁(HexNAc)₂(Deoxyhexose)₁ + (peak 2) (Man)₃(GlcNAc)₂ G1F 1282.96161282.4553 (HexNAc)₁(Deoxyhexose)₁ + (peak 3) (Man)₃(GlcNAc)₂ G0F-Gn1340.0094 1339.4763 (HexNAc)₂ + (peak 4) (Man)₃(GlcNAc)₂ G0 1810.35611809.6403 (Hex)₂(HexNAc)₂(Deoxyhexose)₁ + (peak 5) (Man)₃(GlcNAc)₂ G2F#2, 1906.6223 1905.6343 (Hex)₆ + (Man)₃(GlcNAc)₂ 0.5 μg/ml kif (peak 1)Man9 without fucose 1744.4747 1743.5813 (Hex)₅ + (Man)₃(GlcNAc)₂ (peak2) Man8 without fucose 1582.3702 1581.5283 (Hex)₄ + (Man)₃(GlcNAc)₂(peak 3) Man7 without fucose #3, 1906.4626 1905.6343 (Hex)₆ +(Man)₃(GlcNAc)₂ 1 μg/ml kif (peak 1) Man9 without fucose 1744.33981743.5813 (Hex)₅ + (Man)₃(GlcNAc)₂ (peak 2) Man8 without fucose1582.2029 1581.5283 (Hex)₄ + (Man)₃(GlcNAc)₂ (peak 3) Man7 withoutfucose #4, 1906.7339 1905.6343 (Hex)₆ + (Man)₃(GlcNAc)₂ 1.5 μg/ml kif(peak 1) Man9 without fucose 1744.5612 1743.5813 (Hex)₅ +(Man)₃(GlcNAc)₂ (peak 2) Man8 without fucose 1582.4397 1581.5283(Hex)₄ + (Man)₃(GlcNAc)₂ (peak 3) Man7 without fucose #5, 1906.75111905.6343 (Hex)₆ + (Man)₃(GlcNAc)₂ 2 μg/ml kif (peak 1) Man9 withoutfucose 1744.5969 1743.5813 (Hex)₅ + (Man)₃(GlcNAc)₂ (peak 2) Man8without fucose 1582.4309 1581.5283 (Hex)₄ + (Man)₃(GlcNAc)₂ (peak 3)Man7 without fucose #6, 1906.8270 1905.6343 (Hex)₆ + (Man)₃(GlcNAc)₂ 0.5μg/ml kif (peak 1) Man9 without fucose sup. 3× 1744.6267 1743.5813(Hex)₅ + (Man)₃(GlcNAc)₂ (peak 2) Man8 without fucose 1582.54941581.5283 (Hex)₄ + (Man)₃(GlcNAc)₂ (peak 3) Man7 without fucose #7,1906.6577 1905.6343 (Hex)₆ + (Man)₃(GlcNAc)₂ 1 μg/ml kif (peak 1) Man9without fucose sup. 3× 1744.5094 1743.5813 (Hex)₅ + (Man)₃(GlcNAc)₂(peak 2) Man8 without fucose 1582.4178 1581.5283 (Hex)₄ +(Man)₃(GlcNAc)₂ (peak 3) Man7 without fucose #8, 1906.5720 1905.6343(Hex)₆ + (Man)₃(GlcNAc)₂ 1.5 μg/ml kif (peak 1) Man9 without fucose sup.3× 1744.4355 1743.5813 (Hex)₅ + (Man)₃(GlcNAc)₂ (peak 2) Man8 withoutfucose 1582.3379 1581.5283 (Hex)₄ + (Man)₃(GlcNAc)₂ (peak 3) Man7without fucose #9, 1905.8527 1905.6343 (Hex)₆ + (Man)₃(GlcNAc)₂ 2 μg/mlkif (peak 1) Man9 without fucose sup. 3× 1743.7679 1743.5813 (Hex)₅ +(Man)₃(GlcNAc)₂ (peak 2) Man8 without fucose 1581.7125 1581.5283(Hex)₄ + (Man)₃(GlcNAc)₂ (peak 3) Man7 without fucose^(a)m/z values are for the [M + Na]⁺ ions

Example 11

Additional Example of Enhanced ADCC Activity and Higher FcγRIIIA Bindingfor an Antibody Produced in Cells Treated with Kifunensine

An antibody against a small cell lung carcinoma antigen (antibody C) wasproduced in cells treated with or without kifunensine. The cDNA for theantibody was transiently transfected into HEK293 cells. On day 2, themedium was removed and fresh medium with 2 μg/ml kifunensine or withoutkifunensine was added into T-150 3-layer flasks. Medium was harvestedafter treatment of cells with kifunensine for 3 days. The antibody waspurified from 150˜200 ml of medium. Purity of antibodies was analyzedusing a 4-20% gradient SDS-PAGE, while glycosylation was investigatedusing a lectin blot. Results from SDS-PAGE analysis indicated a highpurity of antibody samples. Much less α-1,6-linked fucose was present inthe antibodies expressed in the presence of kifunensine. MALDI-TOF MSanalysis showed complete modification of glycans into Man9 and Man8without fucose in the antibody C expressed in the presence ofkifunensine.

ADCC activity of the two samples was measured using -cells endogenouslyexpressing the tumor antigen as target cells. The assay was performed byincubating effector cells (human PBMC) and target cells for 5 hrs at50:1 or 100:1 ratio. The results, which are shown in FIGS. 13A and 13B,respectively, indicate significant enhancement of ADCC activity ofantibody C expressed in the presence of kifunensine at low antibodyconcentrations.

The FcγRIIIA binding of kifunensine-treated antibody C was measuredusing BIAcore. HPC4-tagged soluble human FcγRIIIA (Val158) was dilutedto 30 μg/ml in HBS-P buffer, containing 1 mM CaCl₂, and injected into a14,500 RU Anti-HPC4 chip for 3 min at 5 μl/min. All antibodies werediluted to 100 nM in the same buffer and injected after the capture ofsoluble FcγRIIIA for 1 min, followed by 3 min dissociation at 30 μl/min.The surface was regenerated with 2 pulses of 5 mM EDTA in HBS-P buffer.The results from the BIAcore® analysis showed higher FcγRIIIA binding ofthe antibody expressed in the presence of kifunensine as compared to thecontrol antibody (FIG. 14). The results are consistent with the observedADCC enhancement. The modified antibodies have slower off-rates (seeFIG. 14).

Example 12

Titration of Kifunensine Concentration

To investigate the impact of mixed oligomannose and complex-type glycanson antibody function, cells expressing TEM mAb A were treated withvarious amounts of kifunensine. In the first experiment, a CHO cellclone expressing TEM mAb A was treated with 0, 4, 20, 100, 500 and 2500ng/ml of kifunensine for 11 days. The medium was harvested, and theantibody was purified using a protein A column. Fractions containingprotein peaks were pooled and dialyzed into PBS.

Purity of the six antibody samples was confirmed using a 4-20% gradientSDS-PAGE under reducing conditions, followed by staining with Coomassieblue. The results confirmed that these antibodies were pure.

MALDI-TOF MS analysis was performed on these six samples (shown in FIGS.15A-15F). The results showed only a small amount of oligomannosestructures (Man5/Man6) in the antibody from cells treated with 20 ng/mlkifunensine, while 100 ng/ml kifunensine resulted in completeoligomannose structures.

A second titration experiment was performed with a narrower range ofkifunensine concentration, specifically, from 20 to 100 ng/ml. Aftertreatment for 11 days, 50 ml of medium from each treatment condition washarvested, and the antibody was purified. Peak-containing fractions werepooled, buffer-exchanged into PBS using Centricon® filters with repeatedcentrifugation. Aliquots of TEM mAb A antibody samples were applied to a4-12% NuPAGE and stained with Coomassie blue to confirm purity.

The results of MALDI-TOF MS performed on these samples are shown inFIGS. 16A-16E. The glycan structures of the antibody from cells treatedwith 20 and 100 ng/ml kifunensine were similar to those found in thefirst titration experiment, while kifunensine treatment at 40 and 60ng/ml concentrations resulted in antibodies with mixed oligomannose andcomplex-type glycans.

Further, an ADCC assay was performed. The results showed higher ADCCactivity for antibody from cells treated with 2500 ng/ml kifunensine ascompared to antibodies produced without any inhibitors in the firsttitration experiment (FIG. 17A). When five samples from the secondtitration experiment were compared, the antibodies expressed in thepresence of 60, 80 and 100 ng/ml kifunensine showed higher ADCC activitythan the antibodies from cells treated with 20 and 40 ng/ml kifunensine.See FIG. 17B.

The amount of fucosylated and non-fucosylated glycans in antibodies fromeach kifunensine treatment in the second titration experiment wasestimated by calculating the area of each individual glycan peak inMALDI-TOF MS spectra. The percent non-fucosylated glycans was plottedagainst the percent specific target cell lysis and is shown in FIG. 18.The results suggest that TEM mAb A with more than 80% non-fucosylatedglycans has a relatively higher ADCC activity.

In summary, antibodies from cells treated with ≧80 ng/ml kifunensineshowed only oligomannose structures without any fucose. As kifunensineconcentration was lowered to 60 ng/ml, and then further to 20 ng/ml, theantibodies exhibited increasing amounts of complex-type glycans withfucose. Higher ADCC activity was achieved with 60 ng/ml or higherkifunensine concentrations which, in turn, produced more than 80%non-fucosylated glycans.

Example 13

Binding of Human Fc Receptors to Antibodies from Cells Treated withKifunensine

Binding of kifunensine-modified antibody D, another anti-tumor antibody,to various recombinant human Fcγ receptors (FcγRI, FcγRIIA and FcγRIIB)was analyzed using an ELISA format binding assay. 96-well microtiterplates were coated with Fcγ receptors from R&D systems at the followingconcentrations: 0.5 μg/ml of FcγRI, 2.5 μg/ml of FcγRIIA, and 2 μg/ml ofFcγRIIB. Wells were washed 3 times with PBS containing 0.1% Tween 20 andthen blocked with PBS/1% BSA for 1 hr at room temperature. Antibodies,including antibody D from cells treated with or without kifunensineranging from 0 to 100 μg/ml, were added to the wells and incubated atroom temperature for 2 hrs. Antibody concentrations started at 100 μg/mland a 1:2 serial dilution was used. Plates were washed 3 times with PBScontaining 0.1% Tween 20. Bound antibody was detected using 1-hrincubation with a goat anti-human Fab-HRP (1:1500) in PBS containing 1%BSA at room temperature. Plates were then washed and developed with TMB(BioFX lab) at 15 minutes for FcγRI and FcγRIIB and 30 min for FcγRIIA.Reaction was stopped with 2M H₂SO₄ and the absorbance read at 450 nm.Antibody D from cells treated with or without kifunensine bound stronglyto the high affinity FcγRI compared to the low affinity receptors,FcγRIIA and FcγRIIB. The results, presented in FIGS. 19A-19C, suggestedthat kifunensine treatment may improve antibody binding to FcγRIIA andFcγRIIB but not FcγRI.

All numbers expressing quantities of ingredients, cell culture,treatment conditions, and so forth used in the specification, includingclaims, are to be understood as being modified by the term “about”unless the context requires otherwise. The embodiments within thespecification provide an illustration of embodiments of the inventionand should not be construed to limit the scope of the invention. Allpublications, patents, patent applications, and biological sequencescited in this disclosure are incorporated by reference in theirentirety.

1. A pharmaceutical composition comprising a monoclonal antibody or Fcfusion protein comprising an oligomannose-type N-glycan.
 2. Thecomposition of claim 1, wherein the monoclonal antibody or Fc fusionprotein comprises an Fc domain derived from a human antibody.
 3. Thecomposition of claim 1, wherein the monoclonal antibody is human orhumanized.
 4. The composition of claim 1, wherein the monoclonalantibody is directed against a human antigen.
 5. The composition ofclaim 2, wherein the human antibody from which the Fc domain is derivedis of a class selected from the group consisting of IgG, IgA, IgD, IgE,and IgM.
 6. The composition of claim 2, wherein the human antibody fromwhich the Fc domain is derived is of an isotype selected from the groupconsisting of IgG1, IgG2, IgG3, and IgG4.
 7. The composition of claim 6,wherein the Fc domain comprises an amino acid sequence which is at least80% identical to SEQ ID NO:n over the entire length of SEQ ID NO:n,wherein n=1, 2, 3, or
 4. 8. The composition of claim 7, wherein the Fcdomain comprises an amino acid sequence which is at least 90% identicalto SEQ ID NO:1 over the entire length of SEQ ID NO:1.
 9. The compositionof claim 1, wherein the oligomannose-type N-glycans comprise anoligosaccharide selected from the group consisting of Man₉(GIcNAc)₂,Man₈(GIcNAc)₂, Man₇(GIcNAc)₂, Man₆(GIcNAc)₂, and Man₅(GIcNAc)₂.
 10. Thecomposition of claim 1, wherein at least 20% of all N-glycans in thecomposition are Man₅₋₉(GIcNAc)₂.
 11. The composition of claim 1, whereinthe antibody or Fc fusion protein has higher ADCC activity as comparedto the same antibody or Fc fusion protein with complex-type N-glycans.12. The composition of claim 1, wherein the antibody or Fc fusionprotein has higher binding affinity for FcγRIIIA as compared the sameantibody or Fc fusion protein with complex-type N-glycans.
 13. A methodof making the pharmaceutical composition of claim 1, comprising: (a)providing a cell engineered to express the antibody or Fc fusionprotein; (b) culturing the cell under conditions resulting in secretionof the antibody or Fc fusion protein comprising oligomannose-typeN-glycans; and (c) recovering the secreted antibody or Fc fusionprotein.
 14. The method of claim 13, wherein the engineered cell isdeficient in a glycosidase selected from the group consisting ofα-glucosidase I, α-glucosidase II, and α-mannosidase I.
 15. The methodof claim 13, wherein the engineered cell is contacted with an inhibitorof a glycosidase selected from the group consisting of α-glucosidase I,α-glucosidase II, and α-mannosidase I.
 16. The method of claim 15,wherein the inhibitor is a glucosidase I inhibitor selected from thegroup consisting of castanospermine, DNJ, N-alkyl-DNJ, DMDP, andaustraline.
 17. The method of claim 15, wherein the inhibitor is aglucosidase I inhibitor selected from the group consisting of DNJ,N-alkyl-DNJ, N-alkenyl-DNJ, and MDL
 25637. 18. The method of claim 15,wherein the inhibitor is a specific inhibitor of α-mannosidase I. 19.The method of claim 15, wherein the specific inhibitor of α-mannosidaseI is kifunensine.
 20. The method of claim 15, wherein the inhibitor is aα-mannosidase I inhibitor selected from the group consisting of DMJ,N-methyl-DMJ, DIM, and kifunensine.
 21. A method of making an antibodyor Fc fusion protein, comprising: (a) providing a cell engineered toexpress the antibody or Fc fusion protein; (b) culturing the cell in thepresence of kifunensine; and (c) recovering the secreted antibody or Fcfusion protein, wherein the antibody or Fc fusion protein comprises anFc domain derived from IgG1.
 22. The method of claim 21, wherein themammalian cell is a hybridoma, a CHO cell or an NS0 cell.
 23. The methodof claim 20, wherein the cell is incubated in the presence of 0.01 to 20μg/ml kifunensine.
 24. A method of killing a target cell in a mammalcomprising administering to the mammal a pharmaceutical composition ofclaim 1, thereby killing the target cell.
 25. The method of claim 24,wherein the target cell is a cancerous cell, an infected cell, or a cellof the immune system.
 26. The method of claim 24, wherein the mammal ishuman.
 27. The method of claim 24, wherein the mammal has a diseaseselected from the group consisting of cancer, infectious disease,inflammatory disease, and immune-mediated disease.
 28. Use of amonoclonal antibody or Fc fusion protein comprising an oligomannose-typeN-glycan in the manufacture of a medicament for treatment of a diseasein which ADCC-mediated killing of target cells is desired.